Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex

This study demonstrates that psilocybin prolongs stimulus-evoked capillary and surface vessel blood flow in the mouse visual cortex without altering neural activity, suggesting that such neurovascular coupling changes may confound the interpretation of functional connectivity in human neuroimaging studies of psychedelics.

The Gist

The Big Picture: A Traffic Jam in the Brain's "Highway"

Imagine your brain is a bustling city. When a specific part of the city (like the visual cortex, which processes what you see) gets busy, it needs more fuel and oxygen. Normally, the city's delivery trucks (blood vessels) rush in to deliver supplies, and then they quickly leave once the work is done. This smooth coordination is called Neurovascular Coupling.

Scientists have been using a special camera called an fMRI to watch this city. The fMRI doesn't see the workers (neurons) directly; instead, it sees the delivery trucks. It assumes that if the trucks are there, the workers are busy.

The Problem: This study found that when mice take Psilocybin (the active ingredient in "magic mushrooms"), the delivery trucks get stuck. They arrive on time, but they don't leave when they should. They linger in the streets long after the work is finished.

Because the fMRI camera only sees the trucks, it thinks the workers are still busy working hard, even though the workers have actually stopped. This creates a "ghost signal" that tricks scientists into thinking the brain is more connected and active than it really is.

---

The Experiment: Watching the City in Real-Time

To prove this, the researchers didn't just use the fMRI camera. They used a super-powerful microscope (like a drone with a zoom lens) to watch the actual workers and the trucks simultaneously in the brains of awake mice.

1. The Setup: They showed the mice a moving pattern on a screen (like a spinning wheel) to make their visual brain light up.
2. The Baseline: First, they watched what happened normally.
   • The Workers (Neurons): They fired up quickly when the pattern appeared and stopped quickly when it disappeared.
   • The Trucks (Blood Flow): The blood vessels widened to let more blood in, and then quickly narrowed back down once the pattern stopped.
3. The Psilocybin Effect: Then, they gave the mice psilocybin and showed them the same pattern.
   • The Workers: They acted exactly the same! They fired up and stopped at the exact same time. Psilocybin did not change how the neurons behaved.
   • The Trucks: This is where things got weird. The blood vessels opened up, but they refused to close back down quickly. The blood flow stayed high for a long time after the visual stimulus was gone.

The Analogy: Imagine a restaurant.

• Normal: Customers (neurons) order food. The kitchen (blood vessels) rushes to cook and serve. When the customers finish eating, the kitchen stops cooking and the waiters clear the tables immediately.
• With Psilocybin: The customers order and eat exactly the same way. But the waiters keep bringing out fresh plates of food long after the customers have finished eating. If you only looked at the waiters, you'd think the customers were still starving and ordering more, even though they are full.

---

The Culprit: The Serotonin "Remote Control"

The researchers wanted to know why the trucks were stuck. They knew psilocybin works by turning on a specific "remote control" in the brain called the 5-HT2A receptor.

They tested this by giving the mice a "jammer" (a drug called MDL100907) that blocks this remote control before giving them psilocybin.

• Result: When the remote was blocked, the trucks behaved normally again. They didn't get stuck.
• Conclusion: Psilocybin is directly messing with the mechanism that tells blood vessels to "stop flowing" and return to normal. It's like the drug is holding the "gas pedal" down on the blood vessels.

(Note: They also tested another drug called DOI, which is similar to psilocybin. Interestingly, DOI did the opposite—it made the trucks leave too early! This shows that different psychedelic drugs mess with the brain's traffic system in different, unique ways.)

---

The Danger: Why This Matters for Human Studies

This is the most important part for the general public. Most of what we know about how magic mushrooms help with depression or anxiety comes from fMRI scans in humans.

• The Misinterpretation: Because the blood flow stays high for so long after the drug is taken, fMRI scans show "hyper-connectivity." They show different parts of the brain talking to each other intensely.
• The Reality: This study suggests that this "hyper-connectivity" might be a fake signal. It might just be the blood vessels being slow to cool down, not the neurons actually firing in new, complex patterns.

The Analogy: Imagine you are trying to figure out if a city is having a festival by looking at the traffic.

• Scenario A: You see traffic jams everywhere. You assume there is a huge party (neural activity).
• Scenario B: You find out that the traffic lights are broken and stuck on red (psilocybin effect). The cars are just sitting there idling, not because of a party, but because the lights are broken.

If scientists don't realize the "traffic lights" are broken, they will write reports saying, "Wow, this city is incredibly active and connected!" when really, the activity is just a traffic jam caused by the drug.

The Takeaway

1. Psilocybin changes the plumbing, not the people: It changes how blood flows in the brain without necessarily changing how the brain cells are thinking or firing.
2. fMRI can be fooled: Because fMRI measures blood flow, not brain activity directly, psilocybin can make the brain look "more connected" than it actually is.
3. Future Research: When studying psychedelic drugs in humans, scientists need to be very careful. They need to account for this "traffic jam" effect so they don't misinterpret the data. They need to find ways to see the "workers" (neurons) directly, not just the "trucks" (blood).

In short: Psilocybin makes the brain's blood vessels hold on tight, creating a false impression of a super-active brain in our current imaging tools.

Technical Summary

1. Problem Statement

Psychedelics, particularly psilocybin, show significant therapeutic potential for mental health disorders. Functional Magnetic Resonance Imaging (fMRI) is the primary tool used to study their mechanisms of action in humans, relying on the Blood-Oxygenation-Level-Dependent (BOLD) signal as a proxy for neural activity. This proxy depends on Neurovascular Coupling (NVC)—the physiological link where neural activity triggers localized blood flow changes.

The core problem addressed is the assumption that NVC remains unaltered by psychedelic drugs. If psilocybin directly modifies the vascular response to neural activity (independent of the neural activity itself), fMRI interpretations of brain connectivity and activity could be fundamentally flawed. Previous studies have shown that serotonin receptors (targeted by psilocybin) are expressed in vascular cells, suggesting a potential for direct vascular modulation.

2. Methodology

The authors employed a multi-modal imaging approach in awake, head-fixed mice to simultaneously measure neural activity and vascular dynamics before and after drug administration.

• Subjects & Models:

  • Animals: Awake mice expressing GCaMP6f (calcium indicator) in excitatory neurons (CaMKII-positive) in the primary visual cortex (V1).
  • Drugs:
    • Psilocybin (1 mg/kg, I.P.): To test the primary hypothesis.
    • DOI (10 mg/kg, I.P.): Another 5-HT2AR agonist used for comparison to determine drug specificity.
    • MDL100907 (MDL): A selective 5-HT2A receptor antagonist used as a pretreatment to verify receptor involvement.
  • Stimulus: A visual stimulus consisting of drifting gratings (4 directions, 6 seconds duration) to evoke consistent neural and vascular responses.

• Imaging Modalities:

  1. Two-Photon Excited Fluorescence (2PEF) Microscopy:
     • Scale: Microscale (capillaries and individual neurons).
     • Measurements: Simultaneous recording of calcium transients (neural activity), capillary blood flow velocity (via line scanning of red blood cell shadows), and capillary diameter.
     • Resolution: Layer II/III of V1.
  2. Widefield Multimodal Imaging:
     • Scale: Mesoscale (surface vessels and parenchyma).
     • Measurements:
       • Neural Activity: GCaMP6f fluorescence.
       • Blood Flow: Laser Speckle Contrast Imaging (LSCI).
       • Oxygenation: Multi-color reflectance (530nm/560nm) to calculate Hemoglobin (Hb) and Oxygenated Hemoglobin (HbO) concentrations.
       • Vessel Dilation: Vessel width changes.

• Computational Modeling:

  • Whole-Brain Simulation: Used a Balloon-Windkessel model coupled with an 80-region neural mass model (neurolib framework).
  • Goal: To simulate how the empirically observed psilocybin-induced NVC changes would alter BOLD signals and functional connectivity (FC) metrics if neural activity remained constant.

3. Key Contributions

• Direct Decoupling Evidence: Demonstrated that psilocybin alters the hemodynamic response to neural stimuli without changing the underlying neural firing patterns.
• Mechanistic Insight: Identified that the effect is mediated specifically by the 5-HT2A receptor, as it was attenuated by the antagonist MDL100907.
• Drug Specificity: Showed that not all psychedelics have the same NVC effect; while psilocybin prolongs the response, DOI shortens it, highlighting the complexity of serotonin receptor interactions.
• fMRI Interpretation Framework: Provided computational evidence that altered NVC can lead to spurious increases in functional connectivity in fMRI data, challenging current interpretations of psychedelic brain imaging.

4. Key Results

A. Microscale Findings (2PEF)

• Neural Activity: Psilocybin administration did not significantly alter the stimulus-evoked calcium response in V1 neurons. The magnitude and timing of neural activation remained consistent with pre-drug baselines.
• Vascular Response: Psilocybin prolonged the capillary blood flow response.
  • The "rise" phase (initial dilation) was unchanged.
  • The "recovery" phase (return to baseline) was significantly delayed, resulting in a sustained elevation of blood flow velocity after the stimulus offset.
• Baseline Vessels: Psilocybin caused a small but significant increase in baseline capillary diameter and venule diameter, independent of stimulation.

B. Mesoscale Findings (Widefield)

• Neural Activity: Confirmed no change in population-level GCaMP fluorescence.
• Vascular Dynamics:
  • Flow Speed: Arterioles and venules showed a trend toward prolonged flow speed increases, particularly in the recovery phase.
  • Hemoglobin: Psilocybin increased total hemoglobin (HbT) in the recovery phase of arterioles. It also altered the balance of oxygenated vs. deoxygenated hemoglobin, suggesting a delay in the re-oxygenation process.
• Comparison with DOI:
  • Unlike psilocybin, DOI shortened the blood flow recovery phase and reduced vessel dilation, confirming that NVC modulation is drug-specific and not a universal property of 5-HT2AR agonists.

C. Mechanism (Antagonist Study)

• Pretreatment with MDL100907 (5-HT2AR antagonist) attenuated the psilocybin-induced prolongation of the NVC response. This confirms that the 5-HT2A receptor is a primary mediator of this vascular effect.

D. Computational Simulation (BOLD & Connectivity)

• Simulation Setup: The model used the measured "prolonged" flow response of psilocybin vs. the "normal" response, feeding them into the Balloon-Windkessel model while keeping the neural input identical.
• Outcome: The prolonged NVC response resulted in significantly increased pairwise correlations (functional connectivity) across the simulated whole brain.
• Implication: Regions appear hyper-connected in fMRI data simply because the vascular "tail" of the response is longer, causing signals to overlap in time, even though the actual neural communication has not increased.

5. Significance and Implications

• Re-evaluating fMRI Data: This study suggests that many previous human fMRI findings regarding psychedelics (e.g., "increased global connectivity," "disintegration of the default mode network") may be partially or wholly driven by vascular artifacts rather than true changes in neural circuitry.
• Methodological Necessity: Future research on psychedelics using fMRI must account for NVC alterations. The authors suggest combining fMRI with direct neural recording methods (e.g., EEG, intracranial recordings) or using pharmacological blockers to isolate neural effects.
• Physiological Mechanism: The findings suggest that psilocybin interferes with the vasoconstrictive phase of the hemodynamic response (the mechanism that normally restores baseline blood flow), likely via 5-HT2A receptors on vascular smooth muscle, pericytes, or astrocytes.
• Broad Applicability: While focused on the visual cortex, the authors argue that given the high density of 5-HT2A receptors in the prefrontal cortex, similar NVC disruptions likely occur in other brain regions critical for cognition and consciousness.

In conclusion, the paper establishes that psilocybin acts as a vascular modulator that decouples blood flow dynamics from neural activity, necessitating a critical re-interpretation of neuroimaging data in the field of psychedelic therapeutics.